EBS

Emergent BioSolutions Inc. - Q1 2010 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2010. Emergent BioSolutions Inc. is a biopharmaceutical company focused on biodefense and commercial vaccines. The company operates two primary segments: Biodefense (centered on BioThrax, the FDA-approved anthrax vaccine) and Commercial (development of vaccines for infectious diseases). The company is an accelerated filer with 31,040,676 shares of common stock outstanding as of April 30, 2010.

Key Financial Metrics

Note: Debt consists of $15.0 million in line of credit (repaid in April 2010) and $50.0 million in long-term indebtedness.

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 27% to $46.8 million. Product sales dropped 37% to $38.9 million due to a 47% decrease in BioThrax doses delivered, partially offset by an 18% increase in price per dose. Conversely, contracts and grants revenue surged 180% to $7.9 million.
• Profitability: Net income attributable to Emergent fell 77% to $2.5 million. Operating income decreased from $17.3 million to $3.2 million.
• Expense Increases: Research and Development (R&D) expenses rose 25% to $19.9 million, driven by increased spending on biodefense candidates (e.g., anthrax monoclonal therapeutic). Selling, General, and Administrative (SG&A) expenses remained relatively flat at $16.2 million, though they included a $548,000 impairment charge on assets held for sale.
• Cash Flow Improvement: Operating cash flow turned positive at $17.4 million, a significant improvement from a $25.4 million outflow in Q1 2009, primarily due to a $21.5 million decrease in accounts receivable (collections from HHS).

Outlook, Risks, and Contingencies

• Government Dependence: The company derives substantially all revenue from U.S. government contracts for BioThrax. Future revenue is subject to the timing of deliveries and annual appropriations for the Strategic National Stockpile (SNS).
• Manufacturing Expansion: The company is investing in a new manufacturing facility in Lansing, Michigan (approx. $80 million incurred to date) and a facility in Baltimore, Maryland. Qualification and validation of these facilities are critical for future growth.
• Legal Proceedings: Emergent is pursuing three legal actions against Protein Sciences Corporation (PSC) regarding a $10 million loan and asset purchase. The company has recorded a $10 million note receivable and $2.2 million in accrued interest, believing recovery is probable via foreclosure.
• Asset Sales: Two buildings in Frederick, Maryland, classified as "assets held for sale," were impaired by $548,000. An agreement to sell these buildings was entered into in April 2010 but had not closed at the time of filing.
• Risk Factors: Key risks include the potential for government contract termination, manufacturing disruptions, reliance on single-source suppliers for vial filling, and the uncertainty of clinical trial outcomes for pipeline products.

Investor Verification Checklist

• BioThrax Delivery Schedule: Verify the timing of future HHS deliveries under the SNS contract to assess revenue stability.
• Manufacturing Qualification: Monitor the status of FDA qualification and validation for the new Lansing and Baltimore facilities.
• PSC Litigation Status: Track the outcome of foreclosure proceedings and lawsuits against Protein Sciences Corporation to confirm the recoverability of the $12.2 million receivable.
• Debt Covenants: Review the terms of the $65 million debt portfolio, particularly the revolving line of credit, to ensure compliance with financial covenants.
• R&D Pipeline Progress: Evaluate the status of key development programs (e.g., anthrax immune globulin, tuberculosis vaccine) and their reliance on external government funding.